Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BROOKLYN IMMUNOTHERAPEUTICS, INC.

(BTX)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Brooklyn ImmunoTherapeutics Plans Secondary Offering Of 6.28 Million Shares

11/19/2021 | 06:28am EST


ę MT Newswires 2021
All news about BROOKLYN IMMUNOTHERAPEUTICS, INC.
01/20BROOKLYN IMMUNOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/20Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board..
GL
01/20Brooklyn ImmunoTherapeutics, Inc. Appoints Erin S. Enright and Heather B. Redman to its..
CI
01/13Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Prope..
AQ
01/05BROOKLYN IMMUNOTHERAPEUTICS, INC. : Costs Associated with Exit or Disposal Activities (for..
AQ
2021Cantor Fitzgerald Starts Brooklyn ImmunoTherapeutics at Overweight With $9 Price Target
MT
2021BROOKLYN IMMUNOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021Brooklyn Immunotherapeutics, Inc. Announces Resignation of Luba Greenwood as Director E..
CI
2021Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index
AQ
2021BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA : BTX) added to NASDAQ Biotechnology Index
CI
More news
Analyst Recommendations on BROOKLYN IMMUNOTHERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2020
Net income 2020
Net Debt 2020
P/E ratio 2020
Yield 2020
Capitalization 139 M 139 M -
EV / Sales 2020
Capi. / Sales 2021 -
Nbr of Employees 10
Free-Float -
Chart BROOKLYN IMMUNOTHERAPEUTICS, INC.
Duration : Period :
Brooklyn ImmunoTherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BROOKLYN IMMUNOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 2,67 $
Average target price 14,50 $
Spread / Average Target 443%
EPS Revisions
Managers and Directors
Howard J. Federoff President, Chief Executive Officer & Director
Sandra Gurrola Chief Financial Officers
Charles R. Cherington Director
Kevin A. D'Amour Chief Scientific Officer
Jay Sial Chief Administrative & Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
BROOKLYN IMMUNOTHERAPEUTICS, INC.-34.05%143
MODERNA, INC.-34.04%67 921
LONZA GROUP AG-13.71%53 315
IQVIA HOLDINGS INC.-13.38%46 690
SEAGEN INC.-13.93%24 331
ICON PUBLIC LIMITED COMPANY-17.37%20 831